20 Future Czech HealthTech and MedTech Leaders

Nelson Advisors
23 minutes ago
16 min read

The healthcare technology and medical device sectors in the Czech Republic have reached a critical inflection point in 2026, transitioning from a regional innovation hub into a sophisticated global contender.

This evolution is defined by a shift in capital allocation strategies, moving away from fragmented, early-stage experimentation toward a disciplined focus on profitability, clinical validation and scalable business models. As of early 2026, the European healthtech market, valued at approximately $96.68 billion, is navigating a period of strategic evolution influenced by a reorientation of investor priorities. Within this context, the Czech ecosystem, centred largely in the innovation corridors of Prague and Brno, has distinguished itself through a high concentration of deep tech expertise, robust academic spin-off frameworks, and a successful navigation of the rigorous European Medical Device Regulation (MDR).

The resilience of the Czech sector is evidenced by its ability to secure significant funding rounds despite a 7.7% year-on-year decline in total investment for Czech founded startups in 2025, which totalled approximately €540 million. Notably, the healthtech vertical remained a cornerstone of this activity, with high-conviction "mega-deals" and strategic pre-seed rounds signaling a maturation of the ecosystem.

This report identifies and analyses 20 pivotal leaders whose vision and technical execution are shaping the future of Czech healthtech and medtech, categorised by their impact on diagnostic intelligence, chronic disease management, advanced biotechnology and the burgeoning field of digital resilience.

The Vanguard of Artificial Intelligence in Radiology and Diagnostics

The integration of artificial intelligence into clinical workflows represents the most significant technological shift in Czech healthcare between 2024 and 2026. The focus has moved beyond the mere detection of pathologies to the creation of "unified AI platforms" that address the systemic issue of physician burnout and administrative overload.

1. Matěj Misař: Orchestrating the Unified AI Portfolio at Carebot

Matěj Misař, as CEO and co-founder of Carebot, has transformed a startup focused on pneumonia detection into a leading European provider of comprehensive AI solutions for hospitals. Misař’s background in media and news hosting provided a unique skill set for navigating the complex public and regulatory dialogues surrounding AI adoption in medicine. In late 2025, Misař led the launch of the "Horizon by Carebot" portfolio, a strategic move designed to eliminate the technical barriers hospitals face when integrating multiple separate AI vendors.

Under Misař’s leadership, Carebot secured MDR Class IIa certification, a critical milestone that validates the technology for use across the European Union. The company’s focus on "incidental detection", identifying early-stage lung cancer or other pathologies in routine imaging, has provided the clinical and economic justification necessary for widespread adoption. By 2026, Carebot has expanded its footprint beyond the Czech Republic into Southeast Asia (Vietnam) and the Middle East, demonstrating Misař’s ability to scale Czech innovation onto the global stage.

2. Daniel Kvak: The Scientific Architect of AI-Driven Clinical Practice

Daniel Kvak, Carebot’s CTO, represents the next generation of Czech medical scientists who bridge the gap between complex machine learning and actual bedside utility. Kvak’s expertise in developing algorithms for chest X-ray analysis, mammography, and CT scans has earned him international recognition, including a place on the Forbes 30 Under 30 list and the "Personality.AI 2024" award.

Kvak’s technical philosophy emphasises "explainable AI" and rigorous clinical validation. He has co-authored numerous award-winning scientific studies and serves as a reviewer for prestigious journals like European Radiology. By 2026, Kvak’s focus has shifted toward the development of the AI Bones module, which automates fracture detection, and the AI Head CT application for rapid identification of critical brain abnormalities. His work ensures that the Czech Republic remains a leader in the development of tools that reduce the diagnostic burden on radiologists while improving patient outcomes.

Core Leader	Primary Affiliation	Key Achievement (2025-2026)	Global Impact Area
Matěj Misař	Carebot	Launch of Horizon Portfolio	Hospital Workflow Optimization
Daniel Kvak	Carebot	MDR Class IIa Certification for Multiple Modules	Diagnostic Accuracy & Safety
Marek Řehoř	Carebot	Scaling operations to 40+ European hospitals	Operational Scalability
Daniel Dufek	Carebot	Leading development of AI Head CT systems	Emergency Radiology

Cardiovascular Innovation and the Long-Term Monitoring Revolution

The cardiovascular segment is undergoing a paradigm shift from acute care to continuous, AI augmented monitoring. This shift is necessitated by the high prevalence of heart arrhythmias that go undetected during standard clinical observation windows.

3. Vlastimil Hrabal: Scaling Cardiac Diagnostics into the DACH Region

Vlastimil Hrabal, appointed as CEO of Kardi AI in April 2025, has been instrumental in the company’s transition from a promising Czech startup to a Series A-ready international medtech leader. Hrabal’s strategic focus on the DACH region (Germany, Austria, Switzerland) addresses the fundamental challenge of procurement and reimbursement in Western European healthcare systems.

Kardi AI’s core product, an AI-powered chest strap that detects arrhythmias, addresses the "monitoring gap" where traditional 24-hour Holter monitors fail to capture rare or transient events. Hrabal has successfully positioned the company as a provider of "physician-ready outputs," reducing the review burden for cardiologists by delivering evaluated signal reports in an average of five minutes. This technical efficiency, combined with Hrabal’s leadership, has led to a doubling of sales and the launch of pilots across Bulgaria, Poland, Slovakia and Romania.

4. Prof. Tomáš Skála: Bridging Clinical Science and Wearable Technology

As Chief Science Officer and co-founder of Kardi AI, Prof. Tomáš Skála provides the clinical gravitas necessary for a startup to be trusted by national healthcare providers. Skála, a practicing cardiologist, identified the inherent limitations of standard diagnostic tools and sought to create a "globally accessible, medically trusted" solution.

Skála’s work focuses on the clinical validation of the AI layer, which evaluates ECG signals from a long-term chest strap.His research indicates a 30% detection rate for Kardi AI, which is roughly six times higher than traditional short window testing. By 2026, Skála is overseeing clinical trials at university hospitals in Olomouc and Ostrava, further strengthening the evidence base for continuous heart monitoring. His vision extends to making cardiac screening as routine and accessible as checking one's blood pressure, potentially preventing thousands of strokes and heart failure cases annually.

Cardiovascular Leader	AFFILIATION	CORE INNOVATION	FUNDING/STAGE
Vlastimil Hrabal	Kardi AI	International scaling to DACH/CEE	€1.1M Seed+ (2025)
Prof. Tomáš Skála	Kardi AI	AI-driven long-term ECG analysis	Series A Ready (2026)
Stephen Burke	Kardi AI	Co-founder and Executive Director	3 Rounds Raised

The New Frontier of Oncology and Genomic Medicine

The Czech Republic’s biotechnology sector is increasingly defined by university spin-offs that target the fundamental molecular pathways of resistant diseases. These leaders are navigating the longest R&D cycles with high levels of strategic patience and technical precision.

5. Alexander Scheer: Leading the Global Charge Against Resistant Tumors

Alexander Scheer, PhD, is the CEO and CSO of Casinvent Pharma, a Masaryk University spin-off that has become the leading Czech drug discovery company in 2026. Scheer brings over 25 years of international experience in the life science industry, having previously served as CSO for biotech companies in Belgium and France.

At Casinvent, Scheer is advancing a unique "pan-isoform" approach to inhibiting the Casein Kinase 1 (CK1) family of enzymes. While many competitors focus solely on the alpha isoform, Scheer’s team has developed small-molecule inhibitors that simultaneously target the alpha, delta and epsilon isoforms. This approach is designed to bypass the adaptation pathways that cancers use to develop resistance to standard targeted therapies. By mid 2026, Scheer is preparing the company for its IND (Investigational New Drug) filing and entry into clinical Phase Ia/b trials, supported by a Series A funding target of €10-12 million.

6. Tomasz Radaszkiewicz: The Biological Engine Behind Next-Generation Inhibitors

Tomasz Radaszkiewicz serves as the Head of Biology at Casinvent Pharma and is a central figure in the identification of novel therapeutic strategies for Wnt-driven malignancies. Radaszkiewicz’s work involves the rigorous screening of over 500 candidates to select lead compounds with exceptional in vivo efficacy in treating acute myeloid leukemia (AML), melanoma, and pancreatic cancer.

Radaszkiewicz’s role is critical for providing the biological evidence that supports the company’s intellectual property claims and attracts institutional investors like KHAN-I and JIC Ventures. His leadership in biological research has led to significant publications in journals like Cell Reports Medicine, positioning Casinvent as a scientifically superior alternative to current targeted degraders.

7. Petr Cigler: Pioneering Advanced Lipid Nanoparticle Technology

As Chief Scientific Officer of Adalid Sciences, Petr Cigler is addressing the global "delivery bottleneck" for genomic medicines. Adalid, founded in 2024, focuses on the development of lipid nanoparticle (LNP) systems that transport nucleic acids, such as mRNA and gene-editing tools, into human cells.

Cigler’s strategic innovation lies in the company’s "integrated IP portfolio," which focuses on new ionizable compounds and lipid-polymer conjugates. This technology eliminates the need for pharmaceutical companies to source delivery components from multiple vendors, streamlining the development of RNA therapeutics. Under Cigler’s scientific guidance, Adalid has built a diverse library of several patent families focused on flexible and constrained lipids, providing precise control over particle design for specific payloads.

8. Andrea Brazdova: Validating the Future of RNA Delivery

Andrea Brazdova, PhD, is the Head of Biology at Adalid Sciences, where she leads the biological validation of next-generation LNPs. Brazdova is a senior immunologist with postdoctoral training in cellular therapy and immuno-regulation. Her work at Adalid involves linking formulation design with in vitro functionality and in vivo validation, ensuring that nucleic acid medicines reach their clinical impact.

Brazdova’s expertise in immune response characterization is particularly relevant as the industry moves toward localized and systemic delivery routes for complex gene editing. Her leadership in screening LNP candidates against human primary cells ensures that Adalid’s solutions are optimised for safety and efficacy before they reach clinical trials.

Biotech Leader	Affiliation	Technology Focus	Role in Ecosystem
Alexander Scheer	Casinvent Pharma	CK1 $\alpha/\delta/\epsilon$ Inhibitors	Global Strategic Leadership
Tomasz Radaszkiewicz	Casinvent Pharma	Wnt-driven Malignancy Research	Clinical Strategy & Biology
Petr Cigler	Adalid Sciences	LNP Structural Differentiation	IP Development & Chemistry
Andrea Brazdova	Adalid Sciences	Biological Validation of RNA Delivery	Preclinical Translation

Digital Resilience and the Evolution of Mental Health Technology

Mental health has emerged as one of the most attractive investment targets in 2025-2026, with total M&A value in the CNS (Central Nervous System) segment reaching over $30 billion. Czech leaders are pioneering a new category of "digital resilience" that uses AI to mitigate the negative psychological impacts of the digital environment.

9. Jan Romportl: The Visionary Behind "Cognitive Antivirus"

Dr. Jan Romportl, co-founder and CEO of Elin.ai, is a leading expert in cybernetics and AI ethics who has pivoted his expertise toward the growing mental health crisis among Generation Z. Elin.ai, founded in 2023, develops an AI-powered assistant designed to support users in challenging digital environments.

Romportl’s "cognitive antivirus" concept works as a protective layer for the brain, helping users recognise digital overload and algorithmic pressure before they lead to "brainrot" or anxiety. Under Romportl’s leadership, Elin.ai raised a €1 million pre-seed round to further develop its empathetic dialogue LLMs (Large Language Models), which are trained in close collaboration with clinical experts to detect distress signals and provide proactive interventions. His work represents a shift from reactive therapy to preventive digital well-being.

10. Soňa Sikorová: Scaling Digital Therapeutics for Chronic Psychiatry

Soňa Sikorová is the CEO and co-founder of Mindpax, a digital therapeutics company that has become a global leader in the management of bipolar disorder. Mindpax utilises a combination of long-term symptom monitoring (via actigraphic sensors) and targeted digital therapy to improve the clinical condition of patients.

Sikorová has been instrumental in securing large-scale commercialization partnerships, most notably with EVERSANA in the United States, to launch Mindpax’s solution as a regulated digital therapeutic.

Her leadership focuses on evidence generation; Mindpax has conducted years of clinical studies to develop the world's largest dataset of its kind for bipolar patients. By 2026, Sikorová is steering the company toward full integration with U.S. and European healthcare systems, utilizing AI-powered data insights to optimize treatment outcomes in real-time.

11. Jiří Horáček: The Bridge Between Neuroscience and AI Startups

Professor Jiří Horáček is a psychiatrist, neurobiologist, and co-founder of both Elin.ai and Mindpax. His influence in the Czech medical community is profound; he has published over 200 scientific articles and is recognized as one of the "TOP 50 Doctors" in the Czech Republic.

Horáček’s leadership provides the scientific legitimacy required for AI startups to operate in the highly regulated field of clinical psychiatry. He specialises in brain imaging and the use of biomarkers to understand affective disorders. Within Elin.ai, he oversees the training of AI models to ensure they remain non-toxic and empathetic, while at Mindpax, his research into circadian rhythms and suprachiasmatic nuclei (SCN) functioning forms the basis of the company’s monitoring algorithms.

Mental Health Leader	Project	Key Concept	Impact Goal
Jan Romportl	Elin.ai	Cognitive Antivirus	Digital Resilience for Gen Z
Soňa Sikorová	Mindpax	Digital Therapeutics (DTx)	Long-term Bipolar Management
Jiří Horáček	Elin.ai/Mindpax	Empathetic AI Dialogue	Scientifically Validated Well-being
Lukas Krcil	Hedepy	Accessible Online Therapy	Stigma-free Mental Healthcare

Precision Medicine, Longevity and Data Aggregation

The "longevity" market focused on extending the healthy human lifespan is moving from wellness hype toward data-driven precision medicine. Czech leaders are building the platforms that unify disparate health data into actionable insights.

12. Petr Štěpánek: The Entrepreneurial Force Behind Macromo

Petr Štěpánek, CTO and co-founder of Macromo, is a serial entrepreneur who founded his first project at the age of 16 and has since become a central figure in the Prague startup community. Macromo serves as a health data aggregator, providing users with a holistic view of their health by combining DNA results, blood biomarkers and lifestyle data from wearables.

Štěpánek’s vision is to use AI to provide everyone with a "personal health coach" that transforms raw data into clarity. His technical leadership led to the creation of the Macromo Engine, a cloud-based bioinformatics system that contextualises biomarkers over time to identify unique health risks and opportunities. Štěpánek’s proactive approach to fundraising, including independent trips to Silicon Valley to build investor networks, underscores his ambition to take Czech precision medicine technology global.

13. Michal Pohludka: Driving the Clinical and Commercial Bridge

Michal Pohludka, PhD, MBA, is a biochemist with a background in molecular pathology and the CEO of GeneSpector and co-founder of Macromo. Pohludka represents the "business scientist" archetype, capable of navigating the extremely regulated pharmaceutical and medical fields.

Under Pohludka’s leadership, GeneSpector succeeded in the COVID-19 diagnostic market (generating over $25 million in sales) and subsequently pivoted to global diagnostics for kidney disease and other chronic conditions. His strategy focuses on technology transfer, moving projects from the laboratory to the market through licensing or spin-offs. At Macromo, Pohludka leverages this commercial expertise to build partnerships with certified laboratories and ensure that personalised healthcare is both accessible and actionable.

Medtech Infrastructure, Hardware and Biomimetic Innovation

Hardware and physical medical devices remain critical for surgical advancement and patient safety. Czech leaders in this segment are using nanotechnology and biomimetic principles to revolutionise traditional procedures.

14. Markéta Hujerová: Revolutionizing Surgery with Nanofiber Patches

Markéta Hujerová (née Klíčová) is the founder of Nanoflexion, a spin-off from the Technical University of Liberec.Hujerová’s work centres on the development of a nanofiber surgical patch designed to prevent serious complications after intestinal surgery, such as anastomotic leakage and adhesions.

Hujerová’s innovation addresses a critical clinical need: sepsis following colon surgery currently kills up to 22% of affected patients. The nano-patch acts as a biological barrier and carries drugs to suppress inflammation and promote healing. In late 2025, Hujerová signed a pivotal incubation agreement with i&i Prague and Charles University to commercialise the technology and move toward human clinical trials. Her journey from academic research to presenting her project at the World Expo in Osaka illustrates the potential for Czech female scientists to lead global medtech ventures.

15. Miroslav Svoboda: The Snail-Eye Inspiration for Patient Comfort

Miroslav Svoboda, MD, is the CEO and project initiator of Riocath Global, a company that has developed a revolutionary technology for tubular medical devices. The RIOCATH® mechanism, inspired by the unfolding of a snail’s eyestalk, allows for a double-skinned catheter that extends from the inside out.

Svoboda’s invention significantly reduces the risk of infection and tissue damage during catheterisation, a major issue in hospitals worldwide. By virtually eliminating the friction between the catheter casing and the urethra wall, the technology makes for safer and more comfortable patient care, potentially saving healthcare systems millions in antibiotic costs for urinary tract infections. Svoboda’s ability to raise over two million euros from private investors and secure global patents through the European Patent Office marks him as a leader in Czech bio-mechanical innovation.

16. Jiří Kuchyňa: Advancing Scalable AI in Ophthalmology

Jiří Kuchyňa is the CEO of Aireen, a startup that has developed a fundus-camera-agnostic AI system for chronic disease screening through retinal analysis. Under Kuchyňa’s leadership, Aireen achieved a strategic partnership with Optomed to integrate its AI algorithm into handheld fundus cameras, making diabetic retinopathy screening more accessible than ever.

Kuchyňa’s focus on scalability addresses a major public health challenge: the need for sensitive and accurate screening of chronic diseases without requiring a visit to a specialist. By 2026, Kuchyňa is positioning Aireen as a critical component of primary care, enabling early detection of diseases that would otherwise lead to permanent blindness.

Medtech Infrastructure Leader	AFFILIATION	CORE TECHNOLOGY	IMPACT
Markéta Hujerová	Nanoflexion	Nanofiber Surgical Patch	Post-Surgical Sepsis Prevention
Miroslav Svoboda	Riocath Global	Double-skinned Catheter	Infection Risk Reduction
Jiří Kuchyňa	Aireen	Retinal AI Screening	Accessible Ophthalmology
Pavel Rozsíval	Viderai	High-speed Retinal Analysis	Mass-Screening Populations

Emerging Disruptors and the Institutional Backbone

The long-term success of the Czech healthtech ecosystem is contingent upon leaders who build the infrastructure for innovation and venture capital, as well as those who pivot established tech success into the medical field.

17. Jan Studnička: Leading the Mass-Screening Effort at Viderai

Jan Studnička, PhD, is a vitreo-retinal specialist and a core leader at Viderai, an innovative startup aimed at making retinal screening affordable for the general population. Studnička’s clinical expertise in age-related macular degeneration and diabetic retinopathy ensures that Viderai’s AI algorithms deliver specialist-level sensitivity (99%) in routine scans.

Viderai’s mission, supported by Studnička’s clinical leadership, is to lower public healthcare expenses by detecting disorders early through mass-screening applications. By automating the routine work of analysing eye scans, Studnička and his team are increasing the examination capacity of clinics, allowing ophthalmologists to focus on complex surgical cases while the AI handles the bulk of the population screening.

18. Otomar Slama: The Catalyst for Science-to-Business Transfer

Otomar Slama is a co-founder of GeneSpector and a key figure in the Czech "spin-off" ecosystem. His work focuses on the commercialisation of academic research, bridging the gap between discovery and market-ready clinical diagnostics. Slama’s leadership within GeneSpector has helped create a portfolio of solutions for nucleic acid extraction and PCR-based diagnostics that compete with global giants like Natera and GeneDx.

Slama’s influence extends beyond a single company; he is a model for how technology transfer offices and university funds can successfully navigate the complexities of patents, licensing and venture building. His work ensures that the Czech scientific output in biomedicine is not just academic, but industrially viable and beneficial to the national economy.

19. Karel Kubias: Navigating the Venture Capital Life Science Wave

Karel Kubias, MBA, is a Founding Partner at the i&i Biotech Fund (i&i Bio), one of the few VC funds in Central Europe focused exclusively on life science ventures. With over 20 years of leadership experience in pharma and diagnostics (including roles at Merck), Kubias is a critical gatekeeper and accelerator for Czech healthtech leaders.

Under Kubias’s guidance, the i&i Biotech Fund, established in cooperation with the European Investment Fund (EIF), is investing over €45 million into academic spin-offs in drug discovery, medical devices and digital health. Kubias’s role is to identify founders with a "clear edge" and provide the capital and strategic guidance required to take Czech innovations global. His leadership at the fund level is what enables leaders like Alexander Scheer and Markéta Hujerová to move from proof-of-concept to clinical reality.

20. Barbora Šumová: Identifying the Next Wave of Medtech Success

Barbora Šumová, PhD, is a Partner at i&i Bio and a specialist in innovative biotech and medtech ventures. With a PhD in Immunology, Šumová brings deep technical understanding to the investment process, allowing the fund to vet complex biological and technical claims that traditional VCs might miss.

Šumová’s leadership in portfolio management and board leadership is vital for the growth of companies like Casinvent Pharma. She represents a new generation of Czech female investment leaders who are shaping the national landscape by focusing on high-tech innovations that fundamentally improve patient care. Her work ensures that the Czech Republic remains competitive in the European healthtech scene through 2026 and beyond.

Strategic Market Dynamics: The 2026 Narrative

The Czech healthtech landscape is being reshaped by several overarching trends that dictate the strategies of these 20 leaders. The first is the acceleration of digital transformation and AI, with 48% of life science leaders identifying this as the most substantial trend for 2026. The proliferation of generative AI is no longer a peripheral experiment but a core driver of clinical operations and research efficiency.

Furthermore, the rise of MDR as a competitive moat cannot be understated. While the regulation is often viewed as a burden, for Czech leaders like Carebot and Kardi AI, achieving MDR Class IIa certification has become a mark of quality that facilitates market entry into the conservative DACH region and beyond. This regulatory hurdle has effectively filtered out less disciplined competitors, leaving a concentrated group of high-impact players.

The third major trend is the rise of defence-linked biotech and dual-use innovation. The selection of Czech-linked technologies for the NATO DIANA 2026 cohort underscores a new geopolitical reality: biotechnology is now a core pillar of national and regional security. Funding for "human resilience" and "trauma diagnostics" through NATO and EU instruments provides a new, non-dilutive capital source for Czech medtech leaders that was largely absent five years ago.

Investment Landscape and Regional Competitiveness

The distribution of capital in 2025 and 2026 favours those who can demonstrate a "right to grow" through effective capital allocation and the integration of high-growth acquisitions. Although total venture funding in the CEE region remains heavily influenced by a handful of large transactions, the steady flow of seed and seed+ deals in the Czech Republic highlights an ecosystem that is deep and resilient.

Fund/Investor	FOCUS AREA	NOTABLE INVESTMENT
i&i Biotech Fund	Academic Spin-offs, Biotech, Medtech	Casinvent Pharma
JIC Ventures	Deep Tech, SaaS, CEE Early Stage	Casinvent Pharma
Presto Ventures	Early-stage B2B and AI	Elin.ai
Rockaway Ventures	AI-driven Disruptors	ValkaAI (Interactive Video)
DEPO Ventures	Angel-led early-stage medtech	Kardi AI

The emergence of Brno as a secondary but equally powerful hub for life sciences, particularly in oncology and university-driven medtech, complements Prague’s dominance in software-centric healthtech. This regional synergy creates a diverse national portfolio that can weather shifts in specific technological sub-sectors.

Conclusion: The Horizon of 2027 and Beyond

By 2027, the Czech healthtech and medtech sectors are poised to move from "market expansion" into "market leadership" in several niches, specifically AI-enabled radiology and cardiac monitoring. The 20 leaders profiled in this analysis are not just building companies; they are constructing the "AI factories" and "biotech hubs" that will define European healthcare for the next decade.

The core challenge for these leaders moving forward will be navigating the fragmented global landscape. While optimism remains high, with 75% of medtech executives confident in their financial outlook for 2026, this confidence is tempered by geopolitical tensions and pricing pressures. The successful Czech leader of 2027 will be one who adopts an "agile operating model," builds "robust external partnerships," and continues to unite technical discovery with patient care.

As the industry matures beyond the initial AI hype toward measurable productivity, the Czech Republic’s commitment to scientific rigor and regulatory compliance positions it as one of the most promising tech hubs in Europe.

Nelson Advisors > European MedTech and HealthTech Investment Banking

Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital

Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb

Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk

#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech